{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/ACTU",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# ACTUATE THERAPEUTICS, INC. (NASDAQ: ACTU) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is ACTUATE THERAPEUTICS, INC., listed on NASDAQ under ticker ACTU, with ISIN US0050831009. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). The security type is Corporate, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The segment is not on the record. The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 48 filings across 29 filing days in the twelve months to 2026-11-08. The median gap between filing days is 6.5 days. The latest filing is dated 2026-11-02, is of type directors_dealings, and is 6 days before the record date. The exchange median is 6.0 days cadence, 52 filings and 5.0 days latency across 4,359 NASDAQ issuers. The sector median is 6.0 days cadence, 63.0 filings and 4.0 days latency across 526 issuers in 2834 Pharmaceutical Preparations.\n\n## Auditor\n\nThe auditor of record is Crowe LLP, located in Costa Mesa, California. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's investor-relations page names five research houses: B. Riley Securities, Craig-Hallum, H.C. Wainwright & Co., Lucid Capital Markets and Rodman & Renshaw.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe sealed years that hold the issuer are 2022, 2024, 2025 and 2026. The earliest sealed date of the market is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001652935.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/ACTU (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/actuate_i10k-123125.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://actuatetherapeutics.com/investors/stock-information/ (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/ACTU (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2022",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/actuate_i10k-123125.htm",
    "state": "sourced",
    "value": "Crowe LLP"
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/actuate_i10k-123125.htm",
    "state": "sourced",
    "value": "173"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/actuate_i10k-123125.htm",
    "state": "sourced",
    "value": "Costa Mesa, California"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/ACTU",
  "coverage": {
   "count": 5,
   "houses": [
    {
     "analyst": "Mayank Mamtani",
     "house": "B. Riley Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://actuatetherapeutics.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Albert G. Lowe, PhD",
     "house": "Craig-Hallum",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://actuatetherapeutics.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Swayampakula Ramakanth, Ph.D",
     "house": "H.C. Wainwright & Co.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://actuatetherapeutics.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Christopher Liu",
     "house": "Lucid Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://actuatetherapeutics.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Michael G. King, Jr.",
     "house": "Rodman & Renshaw",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://actuatetherapeutics.com/investors/stock-information/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://actuatetherapeutics.com/investors/stock-information/",
     "result": "read: 5 of 5 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 4,
    "corporate_news": 5,
    "director_change": 1,
    "directors_dealings": 18,
    "halt_suspension": 2,
    "prospectus": 5,
    "regulatory_filing": 9,
    "results": 4
   },
   "cadence_median_gap_days": 6.5,
   "filing_days": 29,
   "filings": 48,
   "latency_days": 6,
   "latest": [
    {
     "category": "4",
     "date": "2026-11-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1652935/000119312526443732/xslF345X06/ownership.xml",
     "title": "4 — 4",
     "type": "directors_dealings"
    },
    {
     "category": "4",
     "date": "2026-10-30",
     "source": "https://www.sec.gov/Archives/edgar/data/1652935/000179191726000006/xslF345X06/primary_doc.xml",
     "title": "4 — PRIMARY DOCUMENT",
     "type": "directors_dealings"
    },
    {
     "category": "SCHEDULE 13G",
     "date": "2026-10-30",
     "source": "https://www.sec.gov/Archives/edgar/data/1652935/000175392626002033/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G",
     "type": "regulatory_filing"
    },
    {
     "category": "4",
     "date": "2026-10-30",
     "source": "https://www.sec.gov/Archives/edgar/data/1652935/000169731626000014/xslF345X06/primary_doc.xml",
     "title": "4 — PRIMARY DOCUMENT",
     "type": "directors_dealings"
    },
    {
     "category": "8-K",
     "date": "2026-10-30",
     "source": "https://www.sec.gov/Archives/edgar/data/1652935/000168316826008193/actuate_8k.htm",
     "title": "8-K — CURRENT REPORT (items 3.01)",
     "type": "halt_suspension"
    }
   ],
   "latest_filing_date": "2026-11-02",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ACTU",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-14",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US0050831009"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001652935.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001652935.json",
    "state": "sourced",
    "value": "ACTUATE THERAPEUTICS, INC."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001652935.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001652935.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "ACTU"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:0f2eeea9288feb7b25dc86978239e43164a4c390b6eee2c9cd552222a63072f5",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/ACTU",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:0f2eeea9288feb7b25dc86978239e43164a4c390b6eee2c9cd552222a63072f5",
 "path": "/us/NASDAQ/ACTU",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is ACTUATE THERAPEUTICS, INC., listed on NASDAQ under ticker ACTU, with ISIN US0050831009. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). The security type is Corporate, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The segment is not on the record. The listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 48 filings across 29 filing days in the twelve months to 2026-11-08. The median gap between filing days is 6.5 days. The latest filing is dated 2026-11-02, is of type directors_dealings, and is 6 days before the record date. The exchange median is 6.0 days cadence, 52 filings and 5.0 days latency across 4,359 NASDAQ issuers. The sector median is 6.0 days cadence, 63.0 filings and 4.0 days latency across 526 issuers in 2834 Pharmaceutical Preparations.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Crowe LLP, located in Costa Mesa, California. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names five research houses: B. Riley Securities, Craig-Hallum, H.C. Wainwright & Co., Lucid Capital Markets and Rodman & Renshaw.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The sealed years that hold the issuer are 2022, 2024, 2025 and 2026. The earliest sealed date of the market is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001652935.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ACTU"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/actuate_i10k-123125.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://actuatetherapeutics.com/investors/stock-information/"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/ACTU"
  }
 ],
 "title": "ACTUATE THERAPEUTICS, INC. (ACTU) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}